Earlier studies have shown that faster walking speed is consistently associated with a lower incidence of radiographic and symptomatic knee OA [2]. In addition, it is known that speeds slower than 1.22 m/s are a risk factor for poor health outcomes in OA. The presented study evaluated if walking speed at 1 timepoint, degree of decline in walking speed over 1 year, or both could predict mortality risk over 9 years in knee OA. Data from 4,229 participants included in the Osteoarthritis Initiative were analysed (58% female, age 62.3±9.2 years, BMI 28.5±4.8).
Patients with a walking speed <1.22 m/s with and without decline had a 108% and 96% greater risk of mortality compared with those walking faster without a meaningful decline over the previous year. So, walking slower than 1.22 m/s is associated with increased mortality risk, irrespective of the degree of decline in walking speed during the prior year. In contrast, those walking ≥1.22 m/s who did have a meaningful decline in walking speed over the previous year did not have an increased risk of mortality. Therefore, the authors conclude that with regard to walking speed, a speed of 1.22 m/s seems to be a threshold. Assessing walking speed at 1 timepoint may therefore be sufficient to gauge mortality risk in patients with knee OA.
- Master H, et al. Abstract 2924. ACR 2019. November 8-13, Atlanta (GA/USA).
- Purser J, et al. Arthritis Care Res (Hoboken) 2012;641028-35.
Posted on
Previous Article
« CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients Next Article
TNFi for RA during pregnancy – to stop or not to stop? »
« CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients Next Article
TNFi for RA during pregnancy – to stop or not to stop? »
Table of Contents: ACR 2019
Featured articles
Late-Breaking Abstracts
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications
Proteome abnormalities improve prediction of RA development
RA patients in remission benefit from continued therapy with conventional DMARDs
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
Corticosteroid therapy in GCA: higher platelets – lower relapse rate
Spotlight on Rheumatoid Arthritis
Filgotinib promising in RA patients naïve to methotrexate
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
Biologics show similar activity in patients with elderly-onset RA
Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration
Treatment decisions should not be guided by ultrasound findings
Cancer treatment with checkpoint inhibitors in RA patients?
What is Hot in Systemic Lupus Erythematosus
Anifrolumab succeeds in second phase 3 trial in SLE
Depression closely related to fatigue in SLE patients
Spondyloarthritis – The Beat Goes On
Psoriasis onset determines sequence of symptoms
Higher psychiatric comorbidity in women with PsA
JAK1 inhibition shows remarkable efficacy in AS
CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients
Osteoarthritis – State-of-the-Art
Hand OA: low-dose corticosteroids improve symptoms
Opioids: no quality of life benefits for OA patients
Walking speed is a predictor of mortality in patients with knee OA
Reproductive Issues in Rheumatic Disease
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Prevention of congenital heart block may be possible with hydroxychloroquine
TNFi for RA during pregnancy – to stop or not to stop?
Vasculitis – Novel Treatment Modalities
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis
Prolonged remission after stop of tocilizumab for patients with giant cell arteritis
Best of the Posters
Antifibrotic therapy slows disease progression independent of corticosteroid use
Fibromyalgia patients often experienced abuse in childhood
Related Articles
July 21, 2022
How to treat enthesitis in 2022
June 4, 2022
Downloadable 1-Page Selected Trial PowerPoint Slides
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com